Evidence map›Paper›PMID 42693586›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Organic Nanozyme-Embedded Biotherapeutic Thermosensitive Hydrogel for Extracellular GSH Depletion and Postoperative Tumor Suppression.

Cong Jiang, Zifan Yang, Rong Guo, Meng Suo, Guowei Wang, Dong Chen, Lilin Su, Fuhuan Wang, Shipeng Ning, Kelong Fan and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cong Jiang *Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, P. R. China.
Zifan Yang *Research Center of Nanomedicine Technology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.
Rong Guo *Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, P. R. China.
Meng SuoResearch Center of Nanomedicine Technology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.ORCID https://orcid.org/0009-0004-5061-8172
Guowei WangDepartment of Neurosurgery, The Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
Dong ChenDepartment of Sonography, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, P. R. China.
Lilin SuResearch Center of Nanomedicine Technology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.
Fuhuan WangGeneral Surgery Department, No. 920 Hospital of PLA Joint Logistic Support Force, Kunming, Yunnan, P. R. China.
Shipeng NingResearch Center of Nanomedicine Technology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.
Kelong FanCAS Engineering Laboratory For Nanozyme, Key Laboratory of Biomacromolecules (CAS), CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China.ORCID https://orcid.org/0000-0001-6285-1933
Xuan WangDepartment of Neurosurgery, The Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.

Funding

Guangxi Natural Science Foundation 2026GXNSFBA00640154National Natural Science Foundation of China 82572994
6 · The paper itself

Abstract

Postoperative tumor recurrence remains a major challenge in solid tumor treatment, largely attributed to an immunosuppressive tumor microenvironment and the enrichment of extracellular glutathione (GSH) in the tumor bed, which supports tumor cell survival and proliferation. To address these issues, we designed a multifunctional hydrogel (named SEH) loaded with a novel cyanine nanozyme and Escherichia coli (E. coli). The cyanine nanozyme integrates efficient photothermal therapy (PTT), photodynamic therapy (PDT), and peroxidase-like enzyme activity. SEH is a temperature-sensitive agarose hydrogel. Upon light irradiation, PTT and PDT are simultaneously triggered, inducing hydrogel degradation to release the encapsulated nanozymes and E. coli. PTT and PDT jointly kill residual tumor cells and E. coli, and the death of the latter leads to the release of pathogen-associated molecular patterns (PAMPs). The nanozymes combined with PDT cyclically produce more reactive oxygen species to deplete extracellular GSH, which disrupts the redox balance of residual tumor cells. Furthermore, released PAMPs recruit immune cells to the tumor site, thereby activating anti-tumor immune responses and establishing long-term immune protection. This study provides a novel and effective strategy for postoperative tumor therapy and recurrence inhibition.

Indexed as

bacteriaextracellular GSHorganic nanozymepostoperative tumor therapythermosensitive hydrogel

Identifiers

PMID42693586
PMCPMC13542391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.